Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 13/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.36 |
| ▸ | MC3R | P41968 | 1/20 | 0.36 |
| ▸ | MC1R | Q01726 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE6A | P16499 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6047790 | 0.88 | ROCK1 (0.37) | MC4RMC5RMC3RMC1RROCK1 | |
| SCHEMBL6047835 | 0.87 | ROCK1 (0.38) | MC4RROCK1S1PR1ACSS2PDE5A | |
| SCHEMBL4651530 | 0.85 | MC4R (0.31) | MC4RMC5RMC3RMC1R | |
| SCHEMBL6047848 | 0.83 | MC4R (0.47) | MC4RMC5RMC3RMC1R | |
| SCHEMBL4650503 | 0.82 | CYP1A2 (0.37) | — | |
| SCHEMBL6047761 | 0.82 | ALDH1A1 (0.43) | MC4RMC5RMC3RMC1RCNR2 | |
| SCHEMBL6047770 | 0.81 | MC4R (0.34) | MC4RMC5RMC3RMC1RCNR2 | |
| SCHEMBL6047779 | 0.80 | PDE10A (0.35) | MC4RMC5RMC3RMC1R | |
| SCHEMBL6047759 | 0.80 | — | — | |
| SCHEMBL6047874 | 0.79 | MC4R (0.45) | MC4RMC5RMC3RMC1RCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | claimed |
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148805-A1 | Opthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNN1 | MC4R 1970/4885MC5R 666/4885MC3R 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.